Alnylam Pharmaceuticals (ALNY) and Inovio Pharmaceuticals (INO) both operate in the biotechnology sector, yet they represent very different stages of company maturity and risk. Alnylam is an established RNA interference (RNAi) pioneer with several marketed therapies and consistent revenue, while Inovio is an earlier-stage DNA medicines developer transitioning to its first commercial launch. This stock comparison is relevant for investors and traders weighing the trade-off between a financially solid but recently pressured large-cap biotech and a high-beta, catalyst-driven small-cap. Understanding each company's relative performance, growth drivers, and market positioning helps clarify how these two names fit into a diversified portfolio.
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, a technology that silences disease-causing genes. Its commercial portfolio includes Amvuttra and Onpattro for transthyretin (TTR) amyloidosis, alongside products such as Givlaari and Oxlumo, plus partnered medicines like Leqvio. In recent weeks, the company reported strong third-quarter revenue growth, with net product revenue rising year over year and TTR franchise revenue advancing by roughly 59%.
Despite solid headline results, sentiment has turned cautious. Management guided full-year TTR product sales toward the low end of its forecast range, citing normalizing Amvuttra demand after an initial surge, as well as reimbursement uncertainty tied to the federal 340B drug-pricing program and a more restrictive insurer policy. These concerns contributed to a notable share-price decline, leaving ALNY well below its 52-week high even though the company is now solidly profitable and holds a multi-billion-dollar cash position.
Inovio Pharmaceuticals develops DNA medicines targeting diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its lead candidate, VOCERYQ (formerly INO-3107), recently received FDA accelerated approval as a treatment for recurrent respiratory papillomatosis (RRP), a rare and debilitating airway condition. This marks Inovio's first commercial product and triggered a sharp, multi-day rally in the stock.
That enthusiasm was tempered shortly afterward when the company priced a $75 million public offering to fund launch preparations, and shares pulled back sharply on the associated dilution. Inovio remains pre-profit, with minimal trailing revenue, an ongoing net loss, and a negative equity position, underscoring the execution risk inherent in its commercialization effort. The near-term narrative now centers on the VOCERYQ launch ramp, upcoming quarterly results, and whether the company can extend its cash runway efficiently.
Tickeron maintains a curated section called Trending AI Robots, which highlights a focused selection of the platform's AI trading bots. While Tickeron offers hundreds of automated trading bots that collectively monitor and trade thousands of different tickers, only those best suited to current market conditions earn a place in this featured list. These bots span a broad range of trading styles, strategies, timeframes, performance metrics, and statistical profiles, and each is configured around its own set of tickers. Because market regimes change, the composition of the Trending AI Robots section is regularly refreshed to reflect which systems are currently demonstrating the most relevant positioning. For traders interested in a data-driven, systematic perspective on names like ALNY and INO, exploring Trending AI Robots can provide useful context.
The contrast between these two companies is stark across nearly every dimension. Alnylam operates a diversified, revenue-generating franchise with multiple approved therapies and a pipeline spanning cardio-metabolic, neurologic, and hematologic diseases. Inovio, by contrast, is concentrated around a single newly approved product in a niche rare-disease market. This gives ALNY greater business-model breadth and revenue stability, while INO offers a purer, higher-upside bet on launch execution.
On growth drivers, Alnylam's future hinges on expanding its TTR franchise and advancing late-stage pipeline candidates, but recent guidance cuts and policy risk have weighed on momentum. Inovio's driver is more binary: the success or failure of the VOCERYQ commercial launch. Risk profiles differ accordingly. Alnylam faces pricing and reimbursement headwinds and competitive pressure in the amyloidosis market, while Inovio confronts dilution, limited cash, negative equity, and unproven commercial infrastructure. From a market sentiment standpoint, ALNY is a fundamentally strong but recently de-rated large-cap, whereas INO is a volatile, catalyst-sensitive micro-cap with elevated beta.
Based on observable factors such as trend consistency, financial stability, diversification, and the durability of its catalysts, Tickeron's AI would currently favor ALNY over INO. Alnylam's profitable, multi-product business and substantial cash position provide a more stable foundation than Inovio's single-product, pre-profit profile. While Inovio's FDA approval represents a meaningful and potentially transformative catalyst, it is offset by dilution risk, a limited revenue base, and unproven commercial execution. The AI verdict reflects a probabilistic assessment that Alnylam's relative market positioning and business fundamentals offer a more consistent risk-reward profile in the current environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
On November 13, 2026, the Stochastic Oscillator for ALNY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 50 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, 16 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on ALNY as a result. In 57 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 216 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ALNY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.409) is normal, around the industry mean (3.586). P/E Ratio (26.566) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for INO turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 62 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.586). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALNY | INO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 14 | 100 | |
PRICE GROWTH RATING 1..100 | 84 | 37 | |
P/E GROWTH RATING 1..100 | 97 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INO's Valuation (90) in the Medical Specialties industry is in the same range as ALNY (91) in the Biotechnology industry. This means that INO’s stock grew similarly to ALNY’s over the last 12 months.
INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ALNY (100) in the Biotechnology industry. This means that INO’s stock grew similarly to ALNY’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that ALNY’s stock grew significantly faster than INO’s over the last 12 months.
INO's Price Growth Rating (37) in the Medical Specialties industry is somewhat better than the same rating for ALNY (84) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than ALNY’s over the last 12 months.
INO's P/E Growth Rating (62) in the Medical Specialties industry is somewhat better than the same rating for ALNY (97) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ALNY | INO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 76% |
| Advances ODDS (%) | 14 days ago 73% | 21 days ago 79% |
| Declines ODDS (%) | 12 days ago 69% | 2 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green while INO’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).
ALNY (@Biotechnology) experienced а +1.99% price change this week, while INO (@Biotechnology) price change was -7.28% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -9.73%. For the same industry, the average monthly price growth was -7.91%, and the average quarterly price growth was -21.89%.
ALNY is expected to report earnings on Feb 18, 2027.
INO is expected to report earnings on Mar 02, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INO | 1D Price Change % | ||
|---|---|---|---|---|
| INO | 100% | -2.10% | ||
| AXON - INO | 53% Loosely correlated | -2.85% | ||
| ARRY - INO | 52% Loosely correlated | -3.51% | ||
| LPCN - INO | 41% Loosely correlated | -2.92% | ||
| AMRN - INO | 39% Loosely correlated | -0.62% | ||
| PCSA - INO | 38% Loosely correlated | -7.53% | ||
More | ||||